Alpha Tau Medical Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 8731 http://www.alphataumedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd

Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank - Mar 12th, 2023 12:30 pm
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update - Mar 9th, 2023 9:10 pm
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial - Mar 8th, 2023 10:00 pm
Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters - Mar 3rd, 2023 1:30 pm
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases - Mar 1st, 2023 1:30 pm
Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference - Feb 21st, 2023 9:00 pm
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023 - Dec 13th, 2022 1:00 pm
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 22nd, 2022 9:02 pm
Alpha Tau to Present at Upcoming November Investor Conferences - Nov 9th, 2022 1:00 pm
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology - Oct 21st, 2022 8:01 pm
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy - Sep 8th, 2022 8:05 pm
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Sep 1st, 2022 8:15 pm
Alpha Tau Medical to Participate in Upcoming September Investor Conferences - Aug 30th, 2022 8:05 pm
Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 25th, 2022 8:05 pm
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning - Aug 22nd, 2022 1:00 pm
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials - Jul 5th, 2022 8:01 pm
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™ - Jun 22nd, 2022 8:01 pm
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site - Jun 16th, 2022 8:01 pm
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC - Jun 8th, 2022 1:10 pm
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors - Jun 7th, 2022 8:03 pm